Sema4 Public Company (Nasdaq:SMFR)

Primary contact

🚀 Merged with CM Life Sciences on February 10, 2021. in a SPAC deal worth $800M, raising $500M in the process.
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Specifically, Sema4 is applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The company's health intelligence platform called Centrellis is enabling Sema4 to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
Primary contact

Funding 💰

Total $241M
Select investors BlackRock Innovation Capital, Blackstone Group, Oak HC/FT, Section 32, Connecticut Innovations, Moore Strategic Ventures
Last update: September 4, 2021